SEOUL, Dec. 27 (Korea Bizwire) — The survival rate of South Korean cancer patients topped 70 percent in 2016, sharply up from a decade ago, government data showed Thursday. The rate of people being diagnosed with cancer and living more than five years came to 70.6 percent between 2012 and 2016, up from 54 percent [...]
GWANGJU, Nov. 5 (Korea Bizwire) — Chosun University Hospital in Gwangju announced on Sunday that it is using Watson for Oncology, a medical AI supercomputer designed by IBM Inc., for cancer treatment. Once the information about a patient along with the preliminary diagnosis is entered, Watson delivers the optimum method of treatment by analyzing its [...]
Paris, France, and Cambridge, Massachusetts (USA), Oct. 19 (Korea Bizwire) – NANOBIOTIX (Euronext : NANO – ISIN : FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, presented NBTXR3 positive Phase II/III Act.in.sarc results in patients with locally advanced Soft Tissue Sarcoma at the European Society for Medical Oncology (ESMO) 2018 Congress [...]
SEOUL, Sept. 27 (Korea Bizwire) — The number of Koreans who succumbed to cancer last year was found to be a record high, but compared to other advanced nations, the mortality rate from cancer remained low. Meanwhile, the mortality rate of South Koreans, in general, was low among other leading nations, but deaths from pneumonia, [...]
PARIS, France and CAMBRIDGE, Massachusetts, Sept. 26 (Korea Bizwire) – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, announced today that detailed results of its phase II/III clinical trial of NBTXR3 in patients with soft tissue sarcoma (STS) will be presented by Dr. Sylvie Bonvalot, [...]
NEW YORK, Sept. 25 (Korea Bizwire) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today announced that positive preliminary safety and efficacy data from an ongoing Phase 1/2 clinical trial of CK-101 were presented yesterday [...]
SEJONG, Sept. 19 (Korea Bizwire) – Cancer remained the leading cause of death in South Korea in 2017, with heart-related illness second, government data showed Wednesday. A total of 285,534 South Koreans died in 2017, up 1.7 percent from a year earlier, according to the data from Statistics Korea. This is the largest death toll [...]
DENVER, Jul. 11, 2018 (Korea Bizwire) — The International Association for the Study of Lung Cancer (IASLC) encourages all those involved in molecular testing of lung cancer patients to participate in a global survey designed to assess the implementation of best practices and ultimately develop worldwide guidelines for molecular testing. To take the IASLC Global [...]
SEOUL, Jun. 8 (Korea Bizwire) — The results of a new study show that cancer patients have a higher chance of contracting diabetes that non-patients. A joint team of researchers from the National Cancer Center and Samsung Medical Center revealed the results of the study today. A total of 500,000 samples were analyzed for the [...]
CAMBRIDGE, United Kingdom, Apr. 16 (Korea Bizwire) — AstraZeneca and MedImmune, its global biologics research and development arm, today presented efficacy and safety data from two Phase I trials evaluating Imfinzi (durvalumab) in combination with tremelimumab in 2nd-line immunotherapy-naïve patients with either non-squamous advanced non-small cell lung cancer (NSCLC) (Study 006) or metastatic urothelial carcinoma [...]